By Steven Herne, CEO of Unlearn

At Unlearn, we know that clinical trials present unique challenges for every company, from small biotechs with limited resources to large pharma navigating complex regulatory landscapes. That’s why we’ve built our AI technology to support the specific goals and priorities of diverse stakeholders across the clinical development ecosystem. As a trusted partner, Unlearn collaborates closely with each organization to ensure full data integrity and confidentiality throughout the process of creating and utilizing digital twins of study participants in clinical development. By continuously innovating our technology, we’re addressing key bottlenecks while fundamentally reshaping what’s possible in clinical trials.

‍‍

For Biotechs: Faster, More Feasible Trials

For biotechs, advancing clinical trials comes with intense pressures, such as limited resources, smaller teams, and the critical need to show early safety and efficacy to attract investment or advance assets. Our AI-powered solutions tackle these challenges directly, making it possible to run smaller, faster, regulatory-acceptable trials without compromising the quality of evidence. 

We are the only company innovating with AI models sophisticated enough to create digital twins of individual study participants that forecast every clinical outcome at all future time points, equipping biotechs with meaningful data for early decision-making—a key reason why companies like QurAlis and ProJenX have chosen our technology for progressing their ALS programs with confidence. Digital twins are delivered through a powerful, flexible, yet easy-to-use platform that works with diverse infrastructure and trial needs. For small biotechs, it’s about doing more with less while meeting the highest standards in clinical development.

‍

For Small-Mid-Sized Pharma: Streamlined Trials with a Path to Scale

Our partnerships with small to mid-sized pharma companies have highlighted the dual challenges these organizations face. Not only must they streamline processes for efficiency and scalability, but they also need to make high-stakes go/no-go decisions on assets due to limited capital and a targeted focus on specific diseases. For these companies, success often depends on their ability to pick “winners” with confidence. Unlearn’s digital twins provide critical support by enabling customizable trial designs that add power to studies without inflating costs or timelines, helping these organizations assess early signals for safety and efficacy more effectively.

Mid-sized pharma companies benefit from our Platform’s seamless integration into their existing operations, ensuring trials run efficiently without disruption. With the flexibility to customize digital twin applications and fine-tune models to fit trial data, Unlearn’s Platform adapts to specific study needs, enhancing trial power and supporting robust outcomes. As requirements evolve, Unlearn’s team collaborates closely with partners to ensure the Platform scales alongside their growth, enabling continued support for new goals and therapeutic areas as they emerge.

‍

For Large Pharma: Reducing Risk and Driving Innovation

For larger pharmaceutical companies, the stakes are higher, budgets larger, and new challenges arise. These organizations operate with a portfolio mentality, strategically deciding which assets to build internally and which to acquire from smaller companies, all while considering market opportunities across a range of diseases. Operational complexity, regulatory scrutiny, and a natural skepticism toward new technologies add further hurdles. Unlearn is addressing these complexities head-on. We have developed applications of digital twins to clinical trials that squarely satisfy the regulatory guidelines governing pivotal studies. Likewise, we are able to embed our Platform within secure infrastructures and work closely with internal teams to develop digital twins that integrate seamlessly with in-house data. This close collaboration ensures that data privacy and security remain paramount, building confidence in our technology and its value.

Our experience working with global leaders such as AbbVie and J&J Innovative Medicine has shaped our understanding of what it takes to be an effective partner in this space. We know that for digital twins to become a core part of clinical trial strategy in large organizations, the technology must not only deliver results but also earn trust. That’s why we’re committed to iterative, collaborative development with our partners—working alongside clinical, IT, and quantitative teams to tailor solutions that support strategic decision-making in evaluating and advancing their most promising assets.   

‍

Setting a New Standard in Clinical Trials

Unlearn is redefining what’s possible in clinical trials by fundamentally rethinking how they’re designed and conducted. Our Platform empowers companies of all sizes to harness digital twins, making trials faster, more reliable, and better aligned with today’s high standards in clinical development. We’re here to work alongside industry leaders to ensure participants’ digital twins become indispensable to trial strategy.

To medical directors, clinical teams, and executives: think of the Unlearn Platform as more than just a tool. It’s a dedicated partner in your mission to get better treatments to patients faster. 

Together, we’re not just evolving clinical trials; we’re shaping the future of medicine with AI.